China approves patent to COVID-19 vaccine - (China Daily via NewsPoints Desk)

  • China has granted its first COVID-19 vaccine patent to the adenovirus vector vaccine developed by CanSino Biologics, reported China Daily.

  • According to China's National Intellectual Property Administration, the patent was submitted for application on March 18, and was approved on August 11.

  • The vaccine, dubbed Ad5-nCoV, uses a weakened common cold virus to introduce genetic material from SARS-CoV-2 into the human body.

  • The Phase II trial of the vaccine has found it is safe and can induce an immune response, according to research published in The Lancet last month.

  • However, compared with younger people, older participants generally had significantly lower immune responses, the study found. As a result, elderly people might require an additional dose to induce a stronger immune response.

  • Meanwhile, a late-stage clinical trial, which will include more participants and be conducted overseas, is currently in the pipeline.

To read more NewsPoints articles, click here.

Reference Articles